(HealthDay)—For patients with stage 2 to 3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) does not prolong disease-free or overall survival, according to a study ...
Dec 12, 2012
0
0
(Medical Xpress)—With the perspective of a scientist trained in acupuncture, Alison Adams is well positioned to explain why placebos may be misunderstood—and why they should be understood in the first place.
Nov 2, 2012
0
0
(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of Clinical Oncology.
Jul 13, 2012
0
0
deCODE Genetics, together with their colleagues from the pharmaceutical company Genentech, reported today in the journal Nature the discovery of a variant of the amyloid precursor protein (APP) gene that confers protection ...
Jul 11, 2012
0
0
(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.
Jun 11, 2012
0
0
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...
Jun 5, 2012
0
0
(HealthDay) -- For U.S. veterans with diffuse large B-cell lymphoma (DLBCL), being overweight or obese at time of diagnosis correlates with improved survival, according to a study published online May 29 in the Journal of ...
May 30, 2012
0
0
(HealthDay) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.
May 16, 2012
0
0
(HealthDay) -- Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer Institute report.
Apr 17, 2012
0
0
(HealthDay) -- In patients with locally advanced rectal cancer undergoing radical resection, response to neoadjuvant chemoradiotherapy is an early marker that correlates with rates of recurrence-free survival, distant metastases, ...
Apr 10, 2012
0
0
